Antibody-dependent enhancement (ADE), associated with the Covid vax jabs, has been dismissed as a conspiracy theory. But has been said many times, yesterday’s conspiracy may become today’s truth. ADE occurs when due to a previous infection or vaccination, the body becomes effectively “stuck in gear,” and when faced with a new virus, which is similar, does not attack the virus, but leaves it alone to do its foul viral deeds, or enhances its replication.
A paper in the journal Nature has found that antibodies to the Covid-19 virus, SARS-CoV-2, may lead to ADE. This may be from either infection or via the vaxxes. So, while the mainstream research is slow, the truth is seeping out.
https://www.trialsitenews.com/a/do-covid-19-vaccines-link-to-antibody-dependent-enhancement-c70f95da
“An immunology phenomenon, Antibody-dependent enhancement (ADE) occurs when antibodies, typically generated either in response to a previous infection or vaccination, enhance the entry and replication of a virus or pathogen into host cells rather than neutralizing it. The unfortunate scenario leads to more severe disease outcomes when an individual becomes exposed to the same or a similar pathogen again. Recently, researchers focused on microbiology and immunology from both Australia and America reviewed the phenomenon, observed with other viruses and hypothesized with SARS-CoV-2, the virus behind COVID-19. The study’s corresponding authors include Stephen Kent, a trained infectious disease physician and immunologist, and vaccine scientists at the University of Melbourne, and Brandon DeKosky, a Ph.D. in chemical engineering and pharmaceutical chemistry expert at University of Kansas. In a paper published in Nature, the researchers point to the ongoing rushing of antibody-based drugs and vaccines targeting COVID-19. The authors refer to data from ongoing studies of COVID-19 (and other respiratory viruses), suggesting that anti-SARS-CoV-2 antibodies may exacerbate COVID-19 via ADE. Pointing to past studies involving vaccines targeting syncytial virus and dengue virus that raised ADE risk, in this most recent paper, the experts articulate ADE mechanisms with an eye on mitigation strategies given the substantial portfolio of SARS-CoV-2 vaccine and therapies authorized and in clinical development. What about the risks of ADE against COVID-19? Using published data, the scientists evaluate the risks and opportunities.
Published on September 9 in Nature, “Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies” looks into a complex and potentially disturbing scientific subject in association to the COVID-19 vaccines. Little of this topic is ever raised in mainstream media discussing the COVID-19 vaccines.
https://www.nature.com/articles/s41564-020-00789-5
Nature Microbiology volume 5, pages1185–1191
Abstract
Antibody-based drugs and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are being expedited through preclinical and clinical development. Data from the study of SARS-CoV and other respiratory viruses suggest that anti-SARS-CoV-2 antibodies could exacerbate COVID-19 through antibody-dependent enhancement (ADE). Previous respiratory syncytial virus and dengue virus vaccine studies revealed human clinical safety risks related to ADE, resulting in failed vaccine trials. Here, we describe key ADE mechanisms and discuss mitigation strategies for SARS-CoV-2 vaccines and therapies in development. We also outline recently published data to evaluate the risks and opportunities for antibody-based protection against SARS-CoV-2.”